Abstract
Extracellular vesicles (EVs) hold significant therapeutic potential, yet clinical translation is hindered by production yield and low-efficiency post-isolation engineering methods, highlighting the need for high-density bioreactor systems that support both reliable production and downstream modification. Here, we systematically compare EV output from standard flask cultures, a membrane-based two-chamber bioreactor, and a hollow-fiber bioreactor. Across culture conditions, hollow-fiber bioreactors produced markedly higher EV concentrations while requiring significantly less culture medium, demonstrating major advantages in scalability and resource efficiency. EV production was assessed with nanoparticle tracking analysis, immunoblotting, and transmission electron microscopy. Additionally, proteomic analysis revealed that bioreactor-derived EVs maintained canonical phenotypes and translational feasibility in the context of post-isolation EV engineering. Engineering feasibility was assessed with the first known reported instance of cargo-loading through EV-micelle hybridization, surface-modification through post-insertion of molecules carried by micelles (MCs), and exploitation of Nanoparticle Tracking Analysis (NTA) detection limits. Bioreactor-derived EVs remained readily engineerable, and all engineering experiments required only a small fraction of total EVs produced. Together, these findings demonstrate that bioreactor platforms overcome critical throughput limitations of conventional cultures while producing engineerable EVs. This integrated assessment establishes hollow-fiber and membrane-based bioreactors as scalable, translation-oriented systems for improved EV production and drug delivery potential via post-production engineering.